Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Imago BioSciences, Inc. (IMGO)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 11/09/2022 |
8-K
| Quarterly results|
Docs:
|
"Condensed Consolidated Balance Sheets September 30, December 31, 2022 2021 ASSETS Current assets: Cash and cash equivalents $ 7,293 $ 11,226 Short-term investments 171,121 206,184 Prepaid expenses and other current assets 3,626 3,894 Total current assets 182,040 221,304 Property and equipment, net 2 2 Other long-term assets 4,415 3,480 Total assets $ 186,457 $ 224,786 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 3,898 $ 3,459 Accrued research and development expenses 6,823 4,213 Accrued and other current liabilities 3,117 2,420 Total current liabilities 13,838 10,092 Commitments and contingencies Stockholders’ equity: Common stock, $0.0001 par value; 300,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 33,815,999 and 33,531,743 shar..." |
|
| 08/12/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
8-K
| Quarterly results |
| 03/24/2022 |
8-K
| Quarterly results|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Imago BioSciences Reports Fourth Quarter and Full Year 2021 Financial Results SOUTH SAN FRANCISCO, Calif., March 24, 2022 - Imago BioSciences, Inc. , a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases, today reported financial results for the full year ended December 31, 2021. “I am very gratified by the clinical progress Imago has made in 2021, underlined by the positive and promising interim Phase 2 data in both essential thrombocythemia and myelofibrosis presented at the 2021 American Society of Hematology Annual Meeting. Additionally, Imago made great strides as a company with a successful initial public offering on Nasdaq and expansion of our Board,” said Dr. Hugh Young Rienhoff, Jr., M...." |
|
| 11/10/2021 |
8-K
| Quarterly results|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Imago BioSciences Reports Third Quarter 2021 Financial Results and Provides Recent Business Updates SOUTH SAN FRANCISCO, Calif. - November 10, 2021 - Imago BioSciences, Inc. , a clinical-stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms , today reported financial results for the third quarter ended September 30, 2021 and highlighted recent corporate updates. “Over the third quarter we have built upon the momentum of our recent initial public offering and concurrent private placement that resulted in gross proceeds of $174.6 million to advance our novel LSD1 inhibitor, bomedemstat , for the treatment of hematologic diseases of the bone marrow. We are also pleased to have been added to the Russell 2000 ® Index in late September, which..." |
|
| 08/19/2021 |
8-K
| Quarterly results|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Imago BioSciences, Inc. Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : August 19, 2021 Imago BioSciences, Inc. Delaware 001-40604 45-4915810 329 Oyster Point Blvd., 3rd Floor South San Francisco, California 94080 Registrant's Telephone Number, Including Area Code: 529-5055 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 unde...",
"Imago BioSciences Reports Second Quarter 2021 Financial Results and Provides Recent Business Updates SOUTH SAN FRANCISCO, Calif. - August 19, 2021 - Imago BioSciences, Inc. , a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms , today reported financial results for the second quarter ended June 30, 2021 and highlighted recent corporate updates. “2021 to date has been a transformative year for Imago BioSciences. We have made progress in advancing the clinical development of our lead product candidate bomedemstat for the treatment of blood cancers where the unmet medical need persists. Our growth was anchored by a number of key accomplishments, including our first report on the clinical activity of bomedemstat in essential th..." |
|
|
|